Stay connected and up-to-date in health care news with the Connected Clinician top stories of the week for the week of September 15.
What does the future of healthcare treatment entail? The top headlines of MD Magazine this week may have painted a clear picture. From another biosimilar looking to come down the pipeline, to research on depression's link to cognition and receptors, to an in vitro blood-brain barrier device for stroke patients, recent news has been addled with major discoveries and leaps and bounds of treatment development.
For any stories you missed or wanted to read again, here's the Connection Clinician's top stories of the week!
The CHAMPS study demonstrated that comprehensive asthma interventions proven efficacious in controlled trial settings can be effectively implemented in diverse communities.
Johnson & Johnson's pharmaceuticals company is discontiuing pursuits of triple-combination treatment JNJ-4178.
The BARDA contract funds a specified portion of estimated costs related to the drug’s development.
Researchers trying to unpack the benefits of omega-3 fatty acids were able to trigger a process that appears to reduce inflammation and could be beneficial to patients with MS.
A substance known as epicatechin monomers helps the body release more insulin and respond more efficiently to increased blood glucose, which could in turn benefit type 2 diabetics.
An expert advisory board voted 11-0 in confidence of the vaccine's safety and efficacy trial data Wednesday.
The influenza virus triggered multiple sclerosis relapses in mice models.
The study authors theorized that there are further connections between age and HA, with older adults having significantly more HA than younger adults.
The reSET app is the first mobile medical application to treat substance use disorders.